These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9830624)

  • 1. Oral 5-FU analogues in the treatment of breast cancer.
    Bunnell CA; Winer EP
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):39-43. PubMed ID: 9830624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine in breast cancer: current status.
    Smorenburg CH; Bontenbal M; Verweij J
    Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
    Rivera E; Chang JC; Semiglazov V; Burdaeva O; Kirby MG; Spector T
    Clin Breast Cancer; 2014 Feb; 14(1):26-30. PubMed ID: 24183612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
    Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
    J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
    Lück HJ; Scholz U; Kühnle H; Dethling J
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):74-6. PubMed ID: 10442368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer.
    Scholz U; Lück HJ; Canzler U; Robner D; Kühnle H
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):44-6. PubMed ID: 11098492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
    Nakayama T; Noguchi S
    Oncologist; 2010; 15(1):26-36. PubMed ID: 20080863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving forward with capecitabine: a glimpse of the future.
    Biganzoli L; Martin M; Twelves C
    Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.